Sigumir
What is it?
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Identity / background source ↗
Research context
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
- Working classification
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
- Study methods
- —Small comparative institute report; allocation, blinding and outcome interpretation require caution
- Independent replication
- —Independent replication not established in this collection
- Source access
- —Report reproduction linked; source language and review scope shown per record
- Safety evidence
- —Short-term reports do not establish long-term safety or equivalence to current products
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
View this preparation in the Khavinson evidence map ↗
Linked sources
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Explore the research map and unresolved leads ↗
Sigumir: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement.
- Population / setting
- 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
Named tissue-derived preparation · Journal publication
A. K. Iordanishvili, V. V. Samsonov, L. N. Soldatova, A. A. Polens, G. A. Ryzhak · Adv Gerontol. 2012;25(1):181–186. PMID 22708467
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
- Population / setting
- 62 older patients with temporomandibular joint diseases
- What was checked
- PubMed citation and abstract checked; full paper not reviewed.
Limitations & review scope
- The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired.
- This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.